SOLARIS LAB SRL

Their core work

SOLARIS LAB SRL is an Italian private company based in Porto Mantovano that works on algae-based bio compounds with applications in functional food and gut health. Their most substantive H2020 contribution is in the Algae4IBD project, where they apply microalgae and macroalgae as natural bioactive ingredients targeting inflammatory bowel disease and microbiome modulation. Earlier involvement in biofuel research suggests a background in algae biomass utilization that has since pivoted toward nutraceutical and therapeutic applications. As a non-SME private company participating in large RIA consortia, they likely bring proprietary formulation, production, or testing capabilities that complement academic research partners.

What they specialise in

How they've shifted over time

The early-period data (2016-2018) shows no recorded keywords for SOLARIS LAB's third-party role in WASTE2FUELS, suggesting limited or peripheral involvement in biofuel and waste stream research. By 2021 their participation had shifted entirely toward algae biology applied to human health — microalgae, macroalgae, inflammatory bowel disease, and microbiome — signalling a strategic reorientation from energy feedstocks to food and health biotechnology. The trajectory is a clean pivot: from algae as fuel precursor to algae as therapeutic and functional ingredient.

SOLARIS LAB is moving deeper into algae-derived health solutions, and their long-running Algae4IBD project (ending 2026) positions them as a specialist in translating algae biomass research into clinical and food applications.

How they like to work

SOLARIS LAB has never led an H2020 project, participating either as a standard partner or third party — a profile typical of specialized industrial contributors who bring a specific capability rather than driving the research agenda. Their two projects collectively involved 42 partners across 15 countries, which reflects participation in large RIA consortia rather than tight bilateral arrangements. This suggests they are comfortable operating as one node in a broad international network, likely contributing industrial know-how, pilot-scale production, or proprietary ingredient access.

SOLARIS LAB has collaborated with 42 distinct partners spanning 15 countries across their two projects. Their network is pan-European in character, consistent with the large RIA consortia typical of health and food research programs.

What sets them apart

SOLARIS LAB occupies a specific niche where algae biotechnology intersects with gut health and functional food — a space requiring both biological expertise and food-grade or pharmaceutical processing capability. As a private company (not a university or research institute), they can bridge lab-scale algae research and market-relevant applications in ways that purely academic partners cannot. Their dual background in energy-related algae biomass and health-focused algae compounds gives them a broader view of the algae value chain than most single-sector players.

Highlights from their portfolio

• WASTE2FUELS
  Early third-party involvement in a biofuel-from-waste project signals foundational algae biomass expertise that predates their current health focus.
• Algae4IBD
  A large, long-duration RIA project (2021-2026) targeting inflammatory bowel disease with algae-derived compounds — an unusually direct health application for a private company outside the pharmaceutical mainstream.